key: cord-0736419-0p1kncxn
authors: Aliberti, Stefano; Radovanovic, Dejan; Billi, Filippo; Sotgiu, Giovanni; Costanzo, Matteo; Pilocane, Tommaso; Saderi, Laura; Gramegna, Andrea; Rovellini, Angelo; Perotto, Luca; Monzani, Valter; Santus, Pierachille; Blasi, Francesco
title: Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicenter, cohort study
date: 2020-08-03
journal: Eur Respir J
DOI: 10.1183/13993003.01935-2020
sha: e34d67ad935d6ea27bd00cd27aabcc74675d162f
doc_id: 736419
cord_uid: 0p1kncxn

Helmet CPAP treatment fails in up to 44% of patients with moderate-to-severe hypoxemic acute respiratory failure due to COVID-19 pneumonia

+390250320627; cell: +393394171538; fax: +390250320625

Helmet CPAP treatment fails in up to 44% of patients with moderate-to-severe hypoxemic acute respiratory failure due to COVID-19 pneumonia TEXT Patients with COVID-19 pneumonia can develop hypoxemic acute respiratory failure (hARF) with the need for positive end-expiratory pressure (PEEP). The administration of a continuous positive airway pressure (CPAP) through a helmet improves oxygenation and avoids intubation [1, 2] . A European consensus document suggests that helmet CPAP should be the first therapeutic choice for hARF caused by COVID-19 pneumonia, mainly for minimizing aerosol generation [3] [4] [5] . However, recommendations are based on experts' opinion and consider only evidence obtained in critically ill COVID-19 patients [3] . The Surviving Sepsis Campaign does not recommend the administration of CPAP for the initial management of severe COVID-19 [6] .

In order to evaluate outcomes of COVID-19 patients with pneumonia-related hARF undergoing CPAP treatment, a multicenter, observational, prospective study was conducted between March 7 th , 2020 and April 21 st , 2020 in three high-dependency units (HDU) at two hospitals in Milan, Italy. Adults (≥18 years) with hARF secondary to community-acquired COVID-19 pneumonia undergoing helmet CPAP treatment were consecutively recruited. Indications for helmet CPAP included all the following: a diagnosis of pneumonia as the only cause of hARF and a partial arterial pressure of oxygen to fraction of inspired oxygen (PaO 2 :FiO 2 ) ratio <300 evaluated during oxygen therapy supplied for at least 30 minutes through either a Venturi mask (FiO 2 of at least 0.50) or reservoir mask. CPAP was delivered through high-flow generators (VitalSigns inc., Totowa, USA; 90-140 L/min; Myo 3133A, Pulmodyne) using a helmet (StarMed, Italy) as interface with a PEEP valve (VitalSigns, USA). The presence of other causes of hARF were excluded by clinical evaluation. Patients with at least one of the following criteria were excluded: need for immediate intubation, Glasgow Coma Scale <15, respiratory acidosis, systolic blood pressure (SBP) <90 mmHg despite fluid resuscitation and/or use of vasopressors, swallowing disturbance with increasing risk of aspiration pneumonia, and inability to protect the airways. The Ethical Committees of the two hospitals approved the study (No. 345/2020 and No. 17263/2020) . Demographic, epidemiological, clinical, and laboratory data were recorded at admission. Arterial blood gas analysis and vital signs were recorded before CPAP, and within 6 hours, on day 3 and day 7 after CPAP initiation. Lung recruitability during CPAP treatment was defined as an increase of PaO 2 :FiO 2 ratio of at least 30% from oxygen therapy (baseline) to CPAP treatment (within 6 hours). Severe pneumonia on admission was defined according to latest ATS/IDSA guidelines [7] . Patients were followed up to either 30-days or hospital discharge if still hospitalized at 30 day from HDU admission. The primary outcome was CPAP failure defined as the occurrence of either intubation or death due to any cause during HDU stay. According to local standard operating procedures, indication for intubation included the presence of either ≥1 major or ≥2 minor criteria lasting for ≥1 hour. Major criteria were: respiratory arrest, respiratory pause with unconsciousness, severe hemodynamic instability (i.e., SBP <90 mmHg instead of adequate volume resuscitation), and intolerance to helmet CPAP leading to discontinuation of the device. Minor criteria were: reduction of ≥30% of basal PaO 2 :FiO 2 ratio, PaO 2 :FiO 2 ratio <100, 20% increase of PaCO 2 if basal PaCO 2 was ≥40 mmHg, worsening of alertness, new onset or persistent respiratory distress, SpO 2 <90%, and exhaustion. Achievement of the criteria did not automatically imply intubation of the patient, since this decision was based on a multidisciplinary discussion among the attending physician, the senior attending physician and the critical care physician. Secondary outcomes included the weaning from CPAP to oxygen therapy (CPAP success), all-cause in-hospital and 30-day mortality. Do-Not-Intubate (DNI) order was defined as the decision of the attending physician in charge (after discussion with the critical care physician) to withheld intubation and to use CPAP as "ceiling" treatment considering patient's characteristics (e.g., extremely poor functional status prior on admission, very low predicted probability of hospital survival, patient's own opinion when reliable, frailty score, and comorbidities). Weaning from helmet CPAP was standardized across the three HDUs. Patients on helmet CPAP who did not show signs of respiratory distress (e.g. RR<25) and maintained a SpO 2 >94% with a FiO 2 <50% and a PEEP<=5 cmH 2 O underwent a weaning trial.

Patients maintaining a PaO 2 :FiO 2 ratio >250 on Venturi mask with a FiO 2 <40% for at least 24 hours were considered successfully weaned from helmet CPAP. Qualitative and quantitative variables were summarized with frequencies (absolute and relative, percentage) and central tendency (means and medians) and variability (standard deviations, SD, and interquartile ranges, IQR) indicators, depending on their parametric distribution. A chi-squared or Fisher exact test was computed for qualitative variables; Student t test or Mann Whitney was used for quantitative variables with a parametric or non-parametric distribution, respectively. A Cox proportional hazards regression analysis was carried out to assess the relationship between the composite primary outcome and independent variables. No specific computations were carried out. All the individuals potentially fitting the study selection criteria were recruited when admitted at the two hospitals in Milan. The rate of CPAP failure (either intubation or death) in COVID-19 patients seems to be higher in our study compared with the one recently reported in a multicenter, observational study which enrolled non-COVID-19 pneumonia patients with comparable severity of hARF (44.6% VS. 23%) [8] . Both intubation (21.7% VS. 11%) and mortality (22.9% VS. 12%) rates were also higher in COVID-19 pneumonia than non-COVID-19 pneumonia patients [8] . This finding can be explained by the complex phenomena behind the occurrence of the respiratory failure experienced by COVID-19 patients, which is often paralleled by local vascular micro-thrombosis, and, more importantly, by the absence of a treatment of proven efficacy [9] . Nevertheless, the overall mortality rate of our cohort was comparable to that recently reported in ICU patients [10] . A total of 55.4% of our patients with a median PaO 2 :FiO 2 ratio of 136 and treated with helmet CPAP avoided intubation, and, then, were successfully weaned to oxygen therapy. Unfortunately, prognostic criteria which can discriminate responders to CPAP therapy at HDU admission are still lacking. Finally, a French study enrolled 38 COVID patients with ARF and suggested that CPAP seems to avoid intubation especially in DNI patients [11] . It is difficult to compare our results with those by Oranger and coworkers for different reasons, including the different intervention (Boussignac and oro-nasal CPAP vs. helmet CPAP), unclear severity of respiratory failure (only PaO 2 was reported), inclusion of patients needing O 2 >6 l/min to maintain an SpO 2 >92%, which represents a selection bias (increase of the number of milder patients), and the absence of a mortality rate reported in the CPAP arm.

The present study has several limitations which can limit the generalizability of our results. Among those, the lack of a control group and different standard operating procedures across the three centers, as well as the lack of important information, including the daily length of CPAP treatment, might reduce the inference. However, this is the first experience which evaluated outcomes in COVID-19 patients undergoing helmet CPAP in a multicenter, prospective study. In conclusion, the application of helmet CPAP in COVID-19 patients should be carefully considered and monitored to prevent a delayed endotracheal intubation.

The authors would like to acknowledge the support of all the pulmonologists, respiratory fellows, nurses and respiratory physiotherapists of the COVID-19 HDUs of the Policlinico and Luigi Sacco Hospitals in Milan, Italy. 

Helmet continous positive airway pressure vs oxygen therapy to improve oxygentaion in community-acquires pneumonia: a randomized controlled trial

Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia

Early consensus management for non-ICU ARF SARS-CoV-2 emergency in Italy: from ward to trenches

Protecting healthcare workers from SARS-CoV-2 infection: practical indications

Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal

Management of Critically Ill Adults With COVID-19

Diagnosis and Treatment of Adults With Community-acquired Pneumonia

An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

Noninvasive positive pressure ventilation in pneumonia outside Intensive Care Unit: An Italian multicenter observational study

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2

Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study

Blood Gas Analysis before CPAP treatment

Mean (SD) PaCO 2 , mmHg (n= 157)

Median (IQR) PaO2:FiO 2 ratio

FiO 2 ratio Classes PaO 2 :FiO 2 ratio ≤ 100 156)

Median (IQR) platelets, cell/mm 3 (n= 155)

Median (IQR) ferritin, µg/L (n= 123) 1,484 (832-2,732) 1,558

Median (IQR) IL-6, ng/L (n= 125)

Pneumothorax n (%)Hemodynamic instability, n (%) 0 (0.0) 9 (12.9) 0.001 Intolerance*, n (%) 10 (11.5) 11 (15.7) 0.44

Weaning from CPAP to Oxygen therapy, n (%) 84 (96.6) 6 (8.6) <0.0001Median (